{"id":3872,"date":"2021-09-27T03:40:56","date_gmt":"2021-09-27T03:40:56","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=3872"},"modified":"2023-08-29T18:01:44","modified_gmt":"2023-08-29T18:01:44","slug":"invex-therapeutics-signs-major-collaboration-with-peptron","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=3872","title":{"rendered":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae"},"content":{"rendered":"

\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002<\/p>\n

\u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0cInvex\u5df2\u5c06\u5df2\u83b7\u6279\u51c6\u7684\u836f\u7269Exenatide\u6ce8\u518c\u4e3aPresendin\uff0c\u5c06\u8be5\u7cd6\u5c3f\u75c5\u836f\u7269\u91cd\u65b0\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\uff0c\u5982\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u3001\u6025\u6027\u4e2d\u98ce\u548c\u521b\u4f24\u6027\u8111\u635f\u4f24\u3002<\/p>\n

Peptron\u662f\u4e00\u5bb6\u603b\u90e8\u4f4d\u4e8e\u97e9\u56fd\u5927\u7530\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5f00\u53d1\u4ee5\u80bd\u4e3a\u57fa\u7840\u7684\u53ef\u6301\u7eed\u91ca\u653e\u836f\u7269\uff0c\u5177\u6709\u9ad8\u6280\u672f\u58c1\u5792\uff0c\u53ef\u6cbb\u7597\u5371\u53ca\u751f\u547d\u7684\u6162\u6027\u75be\u75c5\u3002<\/p>\n

\u4e09\u5e74\u524d\uff0c\u8be5\u516c\u53f8\u8fd8\u5728\u8be5\u56fd\u5efa\u7acb\u4e86\u57c3\u585e\u90a3\u80bd\u7684\u751f\u4ea7\u8bbe\u65bd\uff0c\u5e76\u83b7\u5f97\u4e86\u7528\u4e8e\u6cbb\u7597\u5e15\u91d1\u68ee\u6c0f\u75c7\u7684\u4e13\u5229\u3002<\/p>\n

\u5468\u4e00\u4e0a\u5348\uff0c\u82f1\u7ef4\u514b\u65af\u4ece\u6682\u505c\u4ea4\u6613\u4e2d\u5ba3\u5e03\u4e86\u8fd9\u9879\u72ec\u5bb6\u4ea4\u6613\uff0c\u8be5\u4ea4\u6613\u5c06\u4f7f\u82f1\u7ef4\u514b\u65af\u83b7\u5f97Peptron\u7684\u77e5\u8bc6\u4ea7\u6743\uff0c\u5305\u62ec\u5e7f\u6cdb\u7684\u4e34\u5e8a\u524d\u548c\u4e34\u5e8a\u6570\u636e\u5305\uff0c\u4ee5\u53ca\u5176\u4e13\u6709\u5236\u9020\u4e13\u4e1a\u77e5\u8bc6\u548cGMP\u7ea7\u836f\u54c1\u548c\u5b89\u6170\u5242\u3002<\/p>\n

\u6b64\u5916\uff0cPeptron\u8fd8\u5c06\u83b7\u5f97Presendin\u5728\u97e9\u56fd\u7528\u4e8eIIH\u6cbb\u7597\u7684\u72ec\u5bb6\u5546\u4e1a\u6743\u5229\u3002<\/p>\n

\u4e24\u5bb6\u516c\u53f8\u8fd8\u5c06\u4ece\u5f7c\u6b64\u7684\u76d1\u7ba1\u6587\u4ef6\u6570\u636e\u5171\u4eab\u4e2d\u83b7\u76ca\u3002<\/p>\n

\u8be5\u534f\u8bae\u5177\u6709\u6392\u4ed6\u6027\uff0c\u9002\u7528\u4e8e\u5168\u7403\uff0c\u5e76\u4e3a\u4e34\u5e8a\u7814\u7a76\u548c\u9996\u6b21\u5546\u4e1a\u9500\u552e\u540e\u7684\u593410\u5e74\u63d0\u4f9b\u6bcf\u5242\u91cfPresendin\u7684\u4f9b\u5e94\u63d0\u4f9b\u4e00\u4e2a\u786e\u5b9a\u7684\u4ef7\u683c\u3002<\/p>\n

\u5728\u97e9\u56fd\u751f\u4ea7Presendin<\/h2>\n

\u6839\u636e\u8fd9\u9879\u65b0\u534f\u8bae\uff0cPresendin\u5c06\u7531Peptron\u5728\u97e9\u56fd\u4e94\u677e\u7684\u5236\u9020\u5de5\u5382\u5728\u5168\u7403\u4e3aInvex\u751f\u4ea7\u548c\u4f9b\u5e94\u3002\u8be5\u5de5\u5382\u62e5\u6709\u6bcf\u6708\u751f\u4ea7\u8d85\u8fc748,000\u74f6Presendin\u7684\u80fd\u529b\u3002<\/p>\n

Peptron\u9996\u5e2d\u6267\u884c\u5b98Choi Ho-il\u535a\u58eb\u8868\u793a\uff0c\u5408\u4f5c\u7b26\u5408Presendin\u201c\u5728\u5176\u53d1\u5c55\u7684\u8fd9\u4e2a\u91cd\u8981\u9636\u6bb5\u201d\u7684\u4e34\u5e8a\u548c\u5546\u4e1a\u4f9b\u5e94\u8981\u6c42\u3002<\/p>\n

\u4ed6\u8bf4:\u201c\u6211\u4eec\u6700\u5148\u8fdb\u7684GMP\u751f\u4ea7\u8bbe\u65bd\u662fPresendin\u751f\u4ea7\u5e72\u7c89\u6ce8\u5c04\u5242\u7684\u7406\u60f3\u9009\u62e9\uff0c\u800c\u4e0d\u662f\u51bb\u5e72\u6ce8\u5c04\u5242\u6216\u6db2\u4f53\u6ce8\u5c04\u5242\u3002\u201d<\/p>\n

\u5904\u7406\u53bb\u98ce\u9669\u548c\u5feb\u901f\u8ddf\u8fdbInvex\u7684\u53d1\u5c55\u8ba1\u5212<\/h2>\n

Invex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u79f0\uff0c\u6b64\u6b21\u5408\u4f5c\u662f\u8be5\u516c\u53f8\u201c\u5411\u524d\u8fc8\u51fa\u7684\u975e\u5e38\u91cd\u8981\u7684\u4e00\u6b65\u201d\uff0c\u56e0\u4e3a\u5b83\u901a\u8fc7\u63d0\u4f9b\u836f\u7269\u4ea7\u54c1\u3001Peptron\u5173\u952e\u548c\u5e7f\u6cdb\u7684\u6570\u636e\u5305\u53ca\u5176\u5236\u9020\u548c\u6280\u672f\u4e13\u957f\uff0c\u663e\u8457\u964d\u4f4e\u4e86preendin\u5728IIH\u7684\u5f00\u53d1\u98ce\u9669\u3002<\/p>\n

\u4ed6\u8bf4:\u201c\u56e0\u6b64\uff0cInvex\u5c06\u4e0d\u518d\u9700\u8981\u5bf9Presendin\u8fdb\u884c\u989d\u5916\u7684\u52a8\u7269\u8010\u53d7\u6027\u548c\u4eba\u4f53\u836f\u4ee3\u52a8\u529b\u5b66(PK)\u7814\u7a76\uff0c\u8fd9\u964d\u4f4e\u4e86Invex\u7684\u5f00\u53d1\u6210\u672c\uff0c\u5e76\u663e\u8457\u52a0\u5feb\u4e86\u6211\u4eec\u8ba1\u5212\u5728IIH\u8fdb\u884c\u7684\u7b2c\u4e09\u671f\u6ce8\u518c\u7814\u7a76\u3002\u201d<\/p>\n

\u5728\u5468\u4e00\u7684\u6295\u8d44\u8005\u62a5\u544a\u4e2d\uff0cInvex\u6267\u884c\u8463\u4e8bTom Duthy\u535a\u58eb\u8868\u793a\uff0c\u7ed5\u8fc7\u4e4b\u524d\u8981\u6c42\u7684\u5f15\u5165\u6d3b\u52a8\u5c06\u4e3a\u516c\u53f8\u8282\u7701\u7ea6300\u4e07\u6fb3\u5143\uff0c\u5e76\u81f3\u5c11\u8282\u770112\u4e2a\u6708\u7684\u5f00\u53d1\u65f6\u95f4\u3002<\/p>\n

\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u8ba1\u5212\u4e8e2022\u5e74\u4e0a\u534a\u5e74\u8fdb\u884c<\/h2>\n

\u6839\u636eInvex\u7684\u8bf4\u6cd5\uff0cPresendin\u662f\u4e00\u79cd\u6bcf\u5468\u4e00\u6b21\u7684\u76ae\u4e0b\u914d\u65b9Exenatide\uff0c\u5b83\u51cf\u5c11\u4e86\u6ce8\u5c04\u7684\u9891\u7387\uff0c\u4e3a\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5927\u7684\u4fbf\u5229\uff0c\u901a\u5e38\u4f1a\u5bfc\u81f4\u60a3\u8005\u66f4\u5927\u7684\u4f9d\u4ece\u6027\u3002<\/p>\n

\u8be5\u516c\u53f8\u76f8\u4fe1\uff0c\u4e00\u65e6\u4e0a\u5e02\uff0c\u8be5\u836f\u6709\u6f5c\u529b\u4e3aInvex\u548cPeptron\u521b\u9020\u53ef\u89c2\u7684\u6536\u5165\uff0c\u5728\u7f8e\u56fd\u548c\u6b27\u76df\u7684\u5e02\u573a\u4ef7\u503c\u8d85\u8fc716\u4ebf\u6fb3\u5143\uff0c\u9884\u8ba1\u6bcf\u5e74\u589e\u957f3.4%\u3002<\/p>\n

\u9996\u6279\u4e34\u5e8a\u6279\u6b21\u7684Presendin\u9884\u8ba1\u5c06\u4e8e2021\u5e74\u7b2c\u56db\u5b63\u5ea6\u4ecePeptron\u6536\u5230\uff0c\u7528\u4e8e\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n

\u6839\u636e\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u7684\u53cd\u9988<\/a>\uff0cInvex\u6b63\u5728\u7ee7\u7eed\u5236\u5b9a\u5176\u5bf9IIH\u548cPresendin\u7684\u76d1\u7ba1\u7b56\u7565\uff0c\u5e76\u8ba1\u5212\u5728\u7b2c\u56db\u5b63\u5ea6\u521d\u5b8c\u6210\u8fd9\u9879\u5de5\u4f5c\u3002<\/p>\n

\u8be5\u516c\u53f8\u7684\u76ee\u6807\u662f\u57282022\u5e74\u4e0a\u534a\u5e74\u542f\u52a8Presendin\u6ce8\u518c\u7684\u4e09\u671f\u8bd5\u9a8c\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002 \u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0cInvex\u5df2\u5c06\u5df2\u83b7\u6279\u51c6\u7684\u836f\u7269Exenatide\u6ce8\u518c\u4e3aPresendin\uff0c\u5c06\u8be5\u7cd6\u5c3f\u75c5\u836f\u7269\u91cd\u65b0\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\uff0c\u5982\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u3001\u6025\u6027\u4e2d\u98ce\u548c\u521b\u4f24\u6027\u8111\u635f\u4f24\u3002 Peptron\u662f\u4e00\u5bb6\u603b\u90e8\u4f4d\u4e8e\u97e9\u56fd\u5927\u7530\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5f00\u53d1\u4ee5\u80bd\u4e3a\u57fa\u7840\u7684\u53ef\u6301\u7eed\u91ca\u653e\u836f\u7269\uff0c\u5177\u6709\u9ad8\u6280\u672f\u58c1\u5792\uff0c\u53ef\u6cbb\u7597\u5371\u53ca\u751f\u547d\u7684\u6162\u6027\u75be\u75c5\u3002 \u4e09\u5e74\u524d\uff0c\u8be5\u516c\u53f8\u8fd8\u5728\u8be5\u56fd\u5efa\u7acb\u4e86\u57c3\u585e\u90a3\u80bd\u7684\u751f\u4ea7\u8bbe\u65bd\uff0c\u5e76\u83b7\u5f97\u4e86\u7528\u4e8e\u6cbb\u7597\u5e15\u91d1\u68ee\u6c0f\u75c7\u7684\u4e13\u5229\u3002 \u5468\u4e00\u4e0a\u5348\uff0c\u82f1\u7ef4\u514b\u65af\u4ece\u6682\u505c\u4ea4\u6613\u4e2d\u5ba3\u5e03\u4e86\u8fd9\u9879\u72ec\u5bb6\u4ea4\u6613\uff0c\u8be5\u4ea4\u6613\u5c06\u4f7f\u82f1\u7ef4\u514b\u65af\u83b7\u5f97Peptron\u7684\u77e5\u8bc6\u4ea7\u6743\uff0c\u5305\u62ec\u5e7f\u6cdb\u7684\u4e34\u5e8a\u524d\u548c\u4e34\u5e8a\u6570\u636e\u5305\uff0c\u4ee5\u53ca\u5176\u4e13\u6709\u5236\u9020\u4e13\u4e1a\u77e5\u8bc6\u548cGMP\u7ea7\u836f\u54c1\u548c\u5b89\u6170\u5242\u3002 \u6b64\u5916\uff0cPeptron\u8fd8\u5c06\u83b7\u5f97Presendin\u5728\u97e9\u56fd\u7528\u4e8eIIH\u6cbb\u7597\u7684\u72ec\u5bb6\u5546\u4e1a\u6743\u5229\u3002 \u4e24\u5bb6\u516c\u53f8\u8fd8\u5c06\u4ece\u5f7c\u6b64\u7684\u76d1\u7ba1\u6587\u4ef6\u6570\u636e\u5171\u4eab\u4e2d\u83b7\u76ca\u3002 \u8be5\u534f\u8bae\u5177\u6709\u6392\u4ed6\u6027\uff0c\u9002\u7528\u4e8e\u5168\u7403\uff0c\u5e76\u4e3a\u4e34\u5e8a\u7814\u7a76\u548c\u9996\u6b21\u5546\u4e1a\u9500\u552e\u540e\u7684\u593410\u5e74\u63d0\u4f9b\u6bcf\u5242\u91cfPresendin\u7684\u4f9b\u5e94\u63d0\u4f9b\u4e00\u4e2a\u786e\u5b9a\u7684\u4ef7\u683c\u3002 \u5728\u97e9\u56fd\u751f\u4ea7Presendin \u6839\u636e\u8fd9\u9879\u65b0\u534f\u8bae\uff0cPresendin\u5c06\u7531Peptron\u5728\u97e9\u56fd\u4e94\u677e\u7684\u5236\u9020\u5de5\u5382\u5728\u5168\u7403\u4e3aInvex\u751f\u4ea7\u548c\u4f9b\u5e94\u3002\u8be5\u5de5\u5382\u62e5\u6709\u6bcf\u6708\u751f\u4ea7\u8d85\u8fc748,000\u74f6Presendin\u7684\u80fd\u529b\u3002 Peptron\u9996\u5e2d\u6267\u884c\u5b98Choi Ho-il\u535a\u58eb\u8868\u793a\uff0c\u5408\u4f5c\u7b26\u5408Presendin\u201c\u5728\u5176\u53d1\u5c55\u7684\u8fd9\u4e2a\u91cd\u8981\u9636\u6bb5\u201d\u7684\u4e34\u5e8a\u548c\u5546\u4e1a\u4f9b\u5e94\u8981\u6c42\u3002 \u4ed6\u8bf4:\u201c\u6211\u4eec\u6700\u5148\u8fdb\u7684GMP\u751f\u4ea7\u8bbe\u65bd\u662fPresendin\u751f\u4ea7\u5e72\u7c89\u6ce8\u5c04\u5242\u7684\u7406\u60f3\u9009\u62e9\uff0c\u800c\u4e0d\u662f\u51bb\u5e72\u6ce8\u5c04\u5242\u6216\u6db2\u4f53\u6ce8\u5c04\u5242\u3002\u201d \u5904\u7406\u53bb\u98ce\u9669\u548c\u5feb\u901f\u8ddf\u8fdbInvex\u7684\u53d1\u5c55\u8ba1\u5212 Invex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u79f0\uff0c\u6b64\u6b21\u5408\u4f5c\u662f\u8be5\u516c\u53f8\u201c\u5411\u524d\u8fc8\u51fa\u7684\u975e\u5e38\u91cd\u8981\u7684\u4e00\u6b65\u201d\uff0c\u56e0\u4e3a\u5b83\u901a\u8fc7\u63d0\u4f9b\u836f\u7269\u4ea7\u54c1\u3001Peptron\u5173\u952e\u548c\u5e7f\u6cdb\u7684\u6570\u636e\u5305\u53ca\u5176\u5236\u9020\u548c\u6280\u672f\u4e13\u957f\uff0c\u663e\u8457\u964d\u4f4e\u4e86preendin\u5728IIH\u7684\u5f00\u53d1\u98ce\u9669\u3002 \u4ed6\u8bf4:\u201c\u56e0\u6b64\uff0cInvex\u5c06\u4e0d\u518d\u9700\u8981\u5bf9Presendin\u8fdb\u884c\u989d\u5916\u7684\u52a8\u7269\u8010\u53d7\u6027\u548c\u4eba\u4f53\u836f\u4ee3\u52a8\u529b\u5b66(PK)\u7814\u7a76\uff0c\u8fd9\u964d\u4f4e\u4e86Invex\u7684\u5f00\u53d1\u6210\u672c\uff0c\u5e76\u663e\u8457\u52a0\u5feb\u4e86\u6211\u4eec\u8ba1\u5212\u5728IIH\u8fdb\u884c\u7684\u7b2c\u4e09\u671f\u6ce8\u518c\u7814\u7a76\u3002\u201d \u5728\u5468\u4e00\u7684\u6295\u8d44\u8005\u62a5\u544a\u4e2d\uff0cInvex\u6267\u884c\u8463\u4e8bTom Duthy\u535a\u58eb\u8868\u793a\uff0c\u7ed5\u8fc7\u4e4b\u524d\u8981\u6c42\u7684\u5f15\u5165\u6d3b\u52a8\u5c06\u4e3a\u516c\u53f8\u8282\u7701\u7ea6300\u4e07\u6fb3\u5143\uff0c\u5e76\u81f3\u5c11\u8282\u770112\u4e2a\u6708\u7684\u5f00\u53d1\u65f6\u95f4\u3002 \u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u8ba1\u5212\u4e8e2022\u5e74\u4e0a\u534a\u5e74\u8fdb\u884c \u6839\u636eInvex\u7684\u8bf4\u6cd5\uff0cPresendin\u662f\u4e00\u79cd\u6bcf\u5468\u4e00\u6b21\u7684\u76ae\u4e0b\u914d\u65b9Exenatide\uff0c\u5b83\u51cf\u5c11\u4e86\u6ce8\u5c04\u7684\u9891\u7387\uff0c\u4e3a\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5927\u7684\u4fbf\u5229\uff0c\u901a\u5e38\u4f1a\u5bfc\u81f4\u60a3\u8005\u66f4\u5927\u7684\u4f9d\u4ece\u6027\u3002 \u8be5\u516c\u53f8\u76f8\u4fe1\uff0c\u4e00\u65e6\u4e0a\u5e02\uff0c\u8be5\u836f\u6709\u6f5c\u529b\u4e3aInvex\u548cPeptron\u521b\u9020\u53ef\u89c2\u7684\u6536\u5165\uff0c\u5728\u7f8e\u56fd\u548c\u6b27\u76df\u7684\u5e02\u573a\u4ef7\u503c\u8d85\u8fc716\u4ebf\u6fb3\u5143\uff0c\u9884\u8ba1\u6bcf\u5e74\u589e\u957f3.4%\u3002 \u9996\u6279\u4e34\u5e8a\u6279\u6b21\u7684Presendin\u9884\u8ba1\u5c06\u4e8e2021\u5e74\u7b2c\u56db\u5b63\u5ea6\u4ecePeptron\u6536\u5230\uff0c\u7528\u4e8e\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u6839\u636e\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u7684\u53cd\u9988\uff0cInvex\u6b63\u5728\u7ee7\u7eed\u5236\u5b9a\u5176\u5bf9IIH\u548cPresendin\u7684\u76d1\u7ba1\u7b56\u7565\uff0c\u5e76\u8ba1\u5212\u5728\u7b2c\u56db\u5b63\u5ea6\u521d\u5b8c\u6210\u8fd9\u9879\u5de5\u4f5c\u3002 \u8be5\u516c\u53f8\u7684\u76ee\u6807\u662f\u57282022\u5e74\u4e0a\u534a\u5e74\u542f\u52a8Presendin\u6ce8\u518c\u7684\u4e09\u671f\u8bd5\u9a8c\u3002<\/p>\n","protected":false},"author":5,"featured_media":13237,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae<\/title>\n<meta name=\"description\" content=\"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae\" \/>\n<meta property=\"og:description\" content=\"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-27T03:40:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-Peptron-ASX-IXC-Presendin.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae\" \/>\n<meta name=\"twitter:description\" content=\"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/\",\"name\":\"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-09-27T03:40:56+00:00\",\"dateModified\":\"2023-08-29T18:01:44+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae","description":"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae","og_description":"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/","og_site_name":"smallcapsCN","article_published_time":"2021-09-27T03:40:56+00:00","article_modified_time":"2023-08-29T18:01:44+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-Peptron-ASX-IXC-Presendin.jpg","type":"image\/jpeg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_title":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae","twitter_description":"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/","name":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-09-27T03:40:56+00:00","dateModified":"2023-08-29T18:01:44+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u4e0e\u97e9\u56fd\u4e0a\u5e02\u516c\u53f8Peptron (KOSDAQ: 087010)\u7b7e\u7f72\u4e86\u4e00\u9879\u91cd\u8981\u7684\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\uff0c\u6d89\u53ca\u5176\u9886\u5148\u7684\u795e\u7ecf\u7cfb\u7edf\u836f\u7269Presendin\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-signs-major-collaboration-with-peptron\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u4e0ePeptron\u7b7e\u7f72\u91cd\u5927\u5408\u4f5c\u534f\u8bae"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3872"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3872"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3872\/revisions"}],"predecessor-version":[{"id":13236,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3872\/revisions\/13236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13237"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}